Drugs / Netupitant/Palonosetron
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03862144 | May 2016 → Apr 2017 | chemotherapy-induced toxicity | Consorzio Oncotech | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Netupitant/Palonosetron | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03862144 ↗ |
| Known as | NEPA | “Netupitant/Palonosetron (NEPA) will be administered orally at the dose of 300 MG (milligrams) netupitant/0.5 palonosetron 1 hour before the start of any chemotherapy cycle.” NCT03862144 ↗ |
| Action | Inhibit | “netupitant, a new highly selective neurokinin-1 receptor antagonist” PMID 32188417 ↗ Mar 2020 |
| Route | Oral | “Netupitant/Palonosetron (NEPA) will be administered orally at the dose of 300 MG (milligrams) netupitant/0.5 palonosetron 1 hour before the start of any chemotherapy cycle.” NCT03862144 ↗ |